Verrica Pharmaceuticals Stock (NASDAQ:VRCA)
Previous Close
$1.94
52W Range
$1.85 - $11.41
50D Avg
$5.03
200D Avg
$6.03
Market Cap
$84.06M
Avg Vol (3M)
$678.05K
Beta
1.47
Div Yield
-
VRCA Company Profile
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| VIGL | Vigil Neuroscience, Inc. |
| NUVB | Nuvation Bio Inc. |
| IVA | Inventiva S.A. |
| LRMR | Larimar Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| ARQT | Arcutis Biotherapeutics, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |
| LIAN | LianBio |
| KDNY | Chinook Therapeutics, Inc. |
| ETON | Eton Pharmaceuticals, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ASND | Ascendis Pharma A/S |
| ELDN | Eledon Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| FIXX | Q32 Bio Inc. |
| VRNA | Verona Pharma plc |
| GRTX | Galera Therapeutics, Inc. |